All News
Nurse Practitioner Independence
A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices.
Read Article
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.
Read Article
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO
Dr. John Cush RheumNow ( View Tweet)
ANAs and Autoantibodies
https://t.co/PTdXPMCqjP https://t.co/Pbtgaod3uW
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA & Administration are deregulating artificial intelligence & promote widespread use, includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices, clinical decision support software https://t.co/KnkYqCiroa
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Sjogren's Beyond the Dryness
Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness.
https://t.co/2U4Q2aRFec https://t.co/AGq36PT9iZ
Dr. John Cush RheumNow ( View Tweet)
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV
Dr. John Cush RheumNow ( View Tweet)
Spread of Psoriatic Disease from Skin to Joints
Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 21 clinical trials, 2,100 adults, shows cannabis-based medicines (vs placebo) over 2-26 weeks are not effective in treating chronic neuropathy nerve pain, regardless if given as THC of CBD. https://t.co/ZOJrcMGZkr https://t.co/nqCWoFmaWp
Links:
Dr. John Cush RheumNow ( View Tweet)
In Dec 2025, the FDA qualified total hip bone mineral density (BMD) assessed by DXA as a validated surrogate endpoint for osteoporosis clinical trials. Previously OP trials required fracture endpoints as primary efficacy measures, necessitating large 2-5 yr studies https://t.co/5t9rftwX4A
Dr. John Cush RheumNow ( View Tweet)
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/NU553QwCtj
Dr. John Cush RheumNow ( View Tweet)
"I need the courage to start, the wisdom to say good and the religion to make it a habit"
- Ronan Kavanagh of Galway
Dr. John Cush RheumNow ( View Tweet)
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/Fk1HES2UIc
Dr. John Cush RheumNow ( View Tweet)
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/RCaQVXvvfK
Links:
Dr. John Cush RheumNow ( View Tweet)
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/7SACsEYi37
Dr. John Cush RheumNow ( View Tweet)
New for RheumNow Live 2026!
Get more from RheumNow Live 2026—before the meeting begins.
Introducing Dr. Mike Putman, Pre-Learn Director, bringing you speaker-selected Pre-Learns and concise video summaries released weekly for registered attendees.
🎥 Watch Now: This week’s PsA https://t.co/vv5XP7EMfu
Dr. John Cush RheumNow ( View Tweet)
Nursing Shortage Could Worsen Due to Limited Student Loans
On 11/6, a DOE rule-making committee released a new proposed framework excluding nursing from the so-called "professional degree" category -- a plan which, if finalized, would limit nurses' access to certain student https://t.co/0zpznqgdb7
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid & Inflammation Testing
https://t.co/tEkJWGp7DK https://t.co/ZO4BV2mmhn
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Sjogren's Beyond the Dryness
Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness.
https://t.co/4VHRmBm7GC https://t.co/pQV8klTzZV
Dr. John Cush RheumNow ( View Tweet)
